Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Novo Nordisk · Phase 2 · Completed · Enrollment 706

NCT03856047

EudraCT 2018-001945-14

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

74.1288.7475.8461.9857.4776.16
≥5%
43.9753.4935.7924.0615.2839.43
≥10%
≥15%
≥20%
  • Placebo 2.4 mg (NNC0174-0833)
  • Placebo 4.5 mg (NNC0174-0833)
  • Placebo 1.2 mg (NNC0174-0833)
  • Placebo 0.6 mg (NNC0174-0833)
  • Placebo 0.3 mg (NNC0174-0833)
  • Placebo 3.0 mg (Liraglutide)
Show as table
Arm≥5%≥10%≥15%≥20%
NNC0174-0833, 4.5 mgn/rn/rn/rn/r
NNC0174-0833, 2.4 mgn/rn/rn/rn/r
NNC0174-0833, 1.2 mgn/rn/rn/rn/r
NNC0174-0833, 0.6 mgn/rn/rn/rn/r
NNC0174-0833 0.3 mgn/rn/rn/rn/r
Placebo 2.4 mg (NNC0174-0833)74.12%43.97%n/rn/r
Placebo 4.5 mg (NNC0174-0833)88.74%53.49%n/rn/r
Placebo 1.2 mg (NNC0174-0833)75.84%35.79%n/rn/r
Placebo 0.6 mg (NNC0174-0833)61.98%24.06%n/rn/r
Placebo 0.3 mg (NNC0174-0833)57.47%15.28%n/rn/r
Liraglutide 3.0 mgn/rn/rn/rn/r
Placebo 3.0 mg (Liraglutide)76.16%39.43%n/rn/r

Not shown

  • NNC0174-0833, 4.5 mg: endpoint not reported
  • NNC0174-0833, 2.4 mg: endpoint not reported
  • NNC0174-0833, 1.2 mg: endpoint not reported
  • NNC0174-0833, 0.6 mg: endpoint not reported
  • NNC0174-0833 0.3 mg: endpoint not reported
  • Liraglutide 3.0 mg: endpoint not reported